Profile: AMAG Pharmaceuticals, Inc. (AMAG.O)

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its technology for the development and commercialization of a therapeutic iron compound to treat anemia, and imaging agents to aid in the diagnosis of cancer and cardiovascular disease. The Company has one product candidate, Feraheme (ferumoxytol injection), and two approved products, Feridex I.V. and GastroMARK. Feraheme is being developed for use as an intravenous (IV) iron replacement therapeutic agent for the treatment of iron deficiency anemia (IDA) and as a diagnostic agent for vascular enhanced magnetic resonance imaging (MRI) to assess peripheral arterial disease (PAD). Feridex I.V., the Company’s liver contrast agent, is approved and has been sold in the United States, Europe and other countries. In November 2008, ceased manufacturing Feridex I.V. GastroMARK, its oral contrast agent used for delineating the bowel in MRI, is approved and marketed in the United States, Europe, and other countries.

The Company initiated a 108 patient Phase II study of Feraheme in vascular-enhanced MRI for the detection of clinically significant arterial stenosis or occlusion in subjects with intermittent claudication, or leg pain when walking. In addition to its use for the treatment of IDA, Feraheme may also be useful as a vascular enhancing agent in MRI. The Company has the worldwide rights to market and sell ferumoxytol as an imaging agent.